Sicca Syndrome (Sjogren) - Pipeline Review, H2 2015 Is Released Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015 Summary Global Markets Direct s, Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-inclass products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the 1
focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179121/sicca-syndrome-sjogren-pipeline-review-h2-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179121/sicca-syndrome-sjogren-pipeline-review-h2-2015 Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Sicca Syndrome (Sjogren) Overview 8 Therapeutics Development 9 Pipeline Products for Sicca Syndrome (Sjogren) - Overview 9 Pipeline Products for Sicca Syndrome (Sjogren) - Comparative Analysis 10 Sicca Syndrome (Sjogren) - Therapeutics under Development by Companies 11 Sicca Syndrome (Sjogren) - Therapeutics under Investigation by Universities/Institutes 12 Sicca Syndrome (Sjogren) - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Sicca Syndrome (Sjogren) - Products under Development by Companies 16 2
Sicca Syndrome (Sjogren) - Products under Investigation by Universities/Institutes 17 Sicca Syndrome (Sjogren) - Companies Involved in Therapeutics Development 18 Akari Therapeutics, Plc 18 Amgen Inc. 19 Ampio Pharmaceuticals, Inc. 20 Biogen, Inc. 21 Bristol-Myers Squibb Company 22 GlaxoSmithKline Plc 23 MedImmune, LLC 24 Novartis AG 25 Redx Pharma Plc 26 Toleranzia AB 27 UCB S.A. 28 Sicca Syndrome (Sjogren) - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 abatacept - Drug Profile 38 Product Description 38 Mechanism of Action 38 3
R&D Progress 38 ABS-11 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 AMG-557 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Ampion - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 belimumab - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 BIIB-063 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Cellular Immunotherapy for Type 1 Diabetes and Sjogrens Syndrome - Drug Profile 51 Product Description 51 Mechanism of Action 51 4
R&D Progress 51 CFZ-533 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Coversin - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 IMSO-001 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 MEDI-4920 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Recombinant Protein for Sjogren's Syndrome - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Small Molecules to Inhibit BTK for Cancer and Autoimmune disorders - Drug Profile 58 Product Description 58 5
Mechanism of Action 58 R&D Progress 58 UCB-5857 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 VAY-736 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 VM-200 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Sicca Syndrome (Sjogren) - Recent Pipeline Updates 63 Sicca Syndrome (Sjogren) - Dormant Projects 76 Sicca Syndrome (Sjogren) - Discontinued Products 77 Sicca Syndrome (Sjogren) - Product Development Milestones 78 Featured News & Press Releases 78 Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogrens syndrome 78 Appendix 79 Methodology 79 Coverage 79 Secondary Research 79 6
Primary Research 79 Expert Panel Validation 79 Contact Us 79 Disclaimer 80" width="80" height="40" />Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Sicca Syndrome (Sjogren) Overview 8 Therapeutics Development 9 Pipeline Products for Sicca Syndrome (Sjogren) - Overview 9 Pipeline Products for Sicca Syndrome (Sjogren) - Comparative Analysis 10 Sicca Syndrome (Sjogren) - Therapeutics under Development by Companies 11 Sicca Syndrome (Sjogren) - Therapeutics under Investigation by Universities/Institutes 12 Sicca Syndrome (Sjogren) - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Sicca Syndrome (Sjogren) - Products under Development by Companies 16 Sicca Syndrome (Sjogren) - Products under Investigation by Universities/Institutes 17 Sicca Syndrome (Sjogren) - Companies Involved in Therapeutics Development 18 Akari Therapeutics, Plc 18 7
Amgen Inc. 19 Ampio Pharmaceuticals, Inc. 20 Biogen, Inc. 21 Bristol-Myers Squibb Company 22 GlaxoSmithKline Plc 23 MedImmune, LLC 24 Novartis AG 25 Redx Pharma Plc 26 Toleranzia AB 27 UCB S.A. 28 Sicca Syndrome (Sjogren) - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 abatacept - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 ABS-11 - Drug Profile 41 Product Description 41 Mechanism of Action 41 8
R&D Progress 41 AMG-557 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Ampion - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 belimumab - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 BIIB-063 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Cellular Immunotherapy for Type 1 Diabetes and Sjogrens Syndrome - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 CFZ-533 - Drug Profile 52 Product Description 52 9
Mechanism of Action 52 R&D Progress 52 Coversin - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 IMSO-001 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 MEDI-4920 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Recombinant Protein for Sjogren's Syndrome - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Small Molecules to Inhibit BTK for Cancer and Autoimmune disorders - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 UCB-5857 - Drug Profile 59 Product Description 59 10
Mechanism of Action 59 R&D Progress 59 VAY-736 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 VM-200 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Sicca Syndrome (Sjogren) - Recent Pipeline Updates 63 Sicca Syndrome (Sjogren) - Dormant Projects 76 Sicca Syndrome (Sjogren) - Discontinued Products 77 Sicca Syndrome (Sjogren) - Product Development Milestones 78 Featured News & Press Releases 78 Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogrens syndrome 78 Appendix 79 Methodology 79 Coverage 79 Secondary Research 79 Primary Research 79 Expert Panel Validation 79 Contact Us 79 11
Disclaimer 80 Read More http://www.idatainsights.com/reports-landing-page.php?id=179121/sicca-syndromesjogren-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.
12